Concepedia

Publication | Closed Access

PROfound: Phase III study of olaparib versus enzalutamide or abiraterone for metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR) gene alterations

DOI

82

Citations

0

References

2019

Year

Maha Hussain, Joaquı́n Mateo, Karim Fizazi, Fred Saad, Neal D. Shore, Shahneen Sandhu, K.N. Chi, Oliver Sartor, Neeraj Agarwal, David Olmos,
Annals of Oncology

No additional data available for this publication yet. Check back later!